Prostacyclin receptor desensitization is a reversible phenomenon in human platelets

Circulation

Volumn 96, Issue 3, 1997, Pages 756-760

  Fisch, Andreas ^a   Tobusch, Karen ^a   Veit, Kerstin ^a   Meyer, Jürgen ^a   Darius, Harald ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Platelet aggregation inhibitors; Platelets; Prostacyclin; Prostaglandins; Receptors

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYCLIC AMP; ILOPROST; PADGEM PROTEIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN RECEPTOR; SAPONIN; SEROTONIN; TRITIUM;

ARTERY THROMBOSIS; ARTICLE; BINDING SITE; CELL SURFACE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; MALE; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

EID: 0030857516     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.3.756     Document Type: Article

References (16)

1. Darius H, Osborne JA, Reibel DK, Lefer AM. Protective actions of a stable prostacyclin analog in ischemia induced membrane damage in rat myocardium. J Mol Cell Cardiol. 1987;19:243-250.
2. Schrör K, Ohlendorf R, Darius H. Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia. J Pharmacol Exp Ther. 1981;219:243-249.
3. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984;310:1065-1068.
4. 2 receptor activity of human blood platelets in acute ischemic heart disease. Circ Res. 1990;66:932-940.
5. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporal circulation procedures. Drugs. 1992;43:889-924.
6. 2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease: a rebound phenomenon? Prostaglandins. 1981;18:56-58.
7. Sinzinger H, Horsch AK, Silberbauer K. The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease. Thromb Haemost. 1983; 50:885-887.
8. 2 platelet receptors after iloprost infusion in man. Thromb Res. 1987;48:663-669.
9. Yardumian DA, Mackie IJ, Bull H, Goldstone AH, Machin SJ. Platelet hyperaggregability occuring during prolonged continuous intravenous infusion of the prostacyclin analogue ZK 36374. Br J Haematol. 1985;60:109-116.
10. Darius H, Hossmann V, Schrör K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. Klin Wochenschr. 1986;64:545-551.
11. 2 infusion occurs at the receptor level. In: Singinger H, Schror K, eds. Prostaglandins in Clinical Research. New York, NY: Alan R. Liss; 1987:19-23.
12. Alt U, Leigh PJ, Wilkins AJ, Morris PK, MacDermot J. Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br J Clin Pharmacol. 1986;22: 118-119.
13. Jaschonek K, Faul C, Schmidt H, Renn W. Desensitization of platelets to iloprost: loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol. 1988;147: 187-196.
14. 2 receptor activity of platelets in acute ischemic heart disease. Circ Res. 1991;68:245-254.
15. Leigh PJ, MacDermot J. Desensitization of prostacyclin responsiveness in a neuronal hybrid cell line: selective loss of high affinity receptors. Mol Pharmacol. 1985;85:237-247.
16. Krane A, MacDermot J, Keen M. Desensitization of adenylate cyclase responses following exposure to IP prostanoid receptor agonists: homologous and heterologous desensitization exhibit the same time course. Biochem Pharmacol. 1994;47:953-959.